Majadahonda

• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants … Recruiting
  2022-501697-19-01 5 2024-06-18 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• A clinical study to test the effect of niraparib and immunotherapy, for patients with small cell lung cancer (SCLC) that is positive for SLF … Recruiting
  2022-502092-33-00 4 2024-05-31 Extensive-disease small cell lung cancer and high SLFN11-expression
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w … Recruiting
  2023-504151-27-00 5 2024-05-09 Psychosis associated with Alzheimer’s Disease
• Locally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budiga … Recruiting
  2023-504600-28-00 10 2024-05-09 Metastatic Hepatocellular Carcinoma (HCC)
• A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participa … Recruiting
  2023-503208-94-00 6 2024-04-04 Prostate cancer
• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 breast cancer
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho … Recruiting
  2023-505141-48-00 5 2024-03-07 Fibrosis
• A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerabilit … Recruiting
  2023-504835-42-00 4 2024-02-29 Heart Failure (Heart Failure with Reduced Ejection Fraction)
• A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis (ELFIDENCE) Recruiting
  2023-505251-43-00 5 2024-02-28 Primary Biliary Cholangitis
• A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul … Recruiting
  2023-504863-17-00 5 2024-02-21 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus
• Phase III, double-blind, randomised, placebo- and active treatment-controlled clinical trial to evaluate the analgesic efficacy and safety o … Recruiting
  2023-505687-11-00 5 2024-02-06 Acute pain
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 5 2024-02-01 Follicular lymphoma
• A study to test how effective belumosudil tablets are for treating adult participants with chronic lung allograft dysfunction Recruiting
  2023-503462-23-00 5 2023-12-28 Lung transplant rejection
• Mepolizumab and in-office nasal polypectomy in patients with chronic rhinosinusitis (CRS). A three arm study. Recruiting
  2023-505426-34-01 6 2023-12-18 chronic rhinosinusitis (CRS)
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 5 2023-10-26 Hidradenitis Suppurativa
• A Dose Escalation and Expansion Study of BGB-16673 in Patients with B Cell Malignancies Recruiting
  2022-502157-33-00 7 2023-09-18 B-Cell Malignancies
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR) Recruiting
  2024-513562-19-00 5 2023-08-30 End-Stage Kidney Disease
• Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnorma … Recruiting
  2022-501943-34-00 5 2023-06-27 Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
• An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Recruiting
  2022-502415-11-00 5 2023-06-16 Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
• Phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA … Recruiting
  2024-519194-19-00 7 2023-06-06 Chronic lymphocytic leukemia (CLL)

Showing 145–168 of 452 trials